Clinical trials: Metabolic Evaluation
Hyperlipidemia
Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Ethyl Esters
The purpose of this study is to evaluate the safety and efficacy of long-term use of granular capsule formulation of omega-3 fatty acid ethyl esters (Lotriga Granular Capsules) in patients with hyperlipidemia in daily medical…
- Trial name
- NCT02153073
- Testing
- Omega-3 fatty acid ethyl esters
- Where
- 2 sites in Japan
- Volunteers
- 3,084 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men
This study looks at how the new medicine called NNC0480-0389 works in the body of Chinese men when it is given at different doses together with a fixed dose of semaglutide.
- Trial name
- NCT05498610
- Testing
- NNC0480 0389, Semaglutide
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes
This extension study is designed to evaluate the long-term safety and tolerability of colesevelam hydrochloride (WelChol®) in patients with type 2 diabetes.
- Trial name
- NCT00151762
- Testing
- Colesevelam hydrochloride
- Where
- 64 sites in United States, Mexico and 1 more
- Volunteers
- 780 people
- Sponsor
- Daiichi Sankyo
Hypercholesterolemia, Dyslipidemia
Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A
A Randomized, Double blind, Parallel, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A in Patient with primary Hypercholesterolemia or Mixed Dyslipidemia
- Trial name
- NCT05970679
- Testing
- Ezetimibe/Atorvastatin 10/5 mg, Atorvastatin 5mg, Ezetimibe 10mg
- Where
- South Korea
- Volunteers
- 252 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Postmenopausal Osteoporosis
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
The primary objective of this study is to determine the effect of treatment with AGA2118 versus placebo at Month 12 on lumbar spine bone mineral density (BMD) in postmenopausal women with low bone mass.
- Trial name
- ARTEMIS (NCT06577935)
- Testing
- AGA2118
- Where
- 23 sites in United States, Argentina and 2 more
- Volunteers
- 379 people
- Sponsor
- Angitia Biopharmaceuticals
Type 2 Diabetes
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.
- Trial name
- NCT06716424
- Testing
- iGlarLixi (insulin glargine/lixisenatide)
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Sanofi
Obesity
Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks
GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see whether enough calories from glucose are excreted in the urine to cause weight loss.
- Trial name
- NCT00297180
- Testing
- GW869682
- Where
- 3 sites in United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Celiac Disease
Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge
The primary purpose of this study is to characterize changes in gluten-specific T cells and pathology in the small intestine with specific focus on biomarkers likely to change with therapeutic celiac disease (CeD) treatment.
- Trial name
- NCT03409796
- Testing
- Gluten
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Takeda
Methylmalonic Acidemia
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia
This is a study of mRNA-3705 in participants with isolated elevated methylmalonic acid (MMA) due to methylmalonyl-coenzyme A (CoA) mutase (MUT) deficiency.
- Trial name
- NCT04899310
- Testing
- mRNA-3705
- Where
- 11 sites in United States, Canada and 4 more
- Volunteers
- 18 people
- Sponsor
- ModernaTX, Inc.
Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine
A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.
To assess the safety, tolerability and pharmacokinetics of ABT-614 in subjects with type 2 diabetes and chronic kidney disease with albuminuria and to determine whether ABT-614 reduces glomerular filtration rate.
- Trial name
- NCT01464320
- Testing
- ABT-614
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Abbott
Diabetes Mellitus, Type 2
A Study To Evaluate PF-05175157 In Healthy Volunteers
The primary purpose of this study is to evaluate the pharmacodynamics of single oral doses of PF-05175157 in healthy volunteers
- Trial name
- NCT01433380
- Testing
- PF-05175157
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the Body
To investigate rates and routes of excretion, mass balance, pharmacokinetics of parent drug, any known metabolites, and total radioactivity, metabolite profiling, metabolite identification, if suitable assays are available…
- Trial name
- NCT04267276
- Testing
- Part 1: BI 1265162 - intravenous, Part 2: BI 1265162 - oral
- Where
- Netherlands
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 1
Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India
This study is conducted in Asia. The aim of this study is to evaluate long term safety and efficacy in patients with diabetes mellitus in routine clinical practice in India.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT02230618
- Testing
- insulin degludec/insulin aspart
- Where
- 35 sites in India
- Volunteers
- 1,029 people
- Sponsor
- Novo Nordisk A/S
Healthy, Overweight and Obese Adults
A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults
A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of single and multiple dose regimens of SYNT-101 in healthy and overweight adults.
- Trial name
- NCT07307274
- Testing
- SYNT101
- Where
- Australia
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Syntis Bio
Frontotemporal Dementia, FTD
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN).
- Conditions
- Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal
- Trial name
- ASPIRE-FTD (NCT06064890)
- Testing
- Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101
- Where
- 19 sites in United States, Belgium and 7 more
- Volunteers
- 18 people
- Sponsor
- AviadoBio Ltd
Diabetes Mellitus, Type 1
At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)
This study was an extension of the NIH-sponsored At-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who developed clinical type 1 diabetes after the…
- Trial name
- NCT04270942
- Testing
- teplizumab 1 mg/mL
- Where
- 8 sites in United States
- Volunteers
- 6 people
- Sponsor
- Provention Bio, a Sanofi Company
Fabry Disease
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease
Primary Objective: To assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and exploratory efficacy of GZ/SAR402671 in enzyme replacement therapy treatment-naïve adult male participants diagnosed with Fabry disease.
- Trial name
- NCT02228460
- Testing
- GZ/SAR402671
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Genzyme, a Sanofi Company
Lipoprotein Disorder
A Study of DII235 in Adults With Elevated Lipoprotein(a)
The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).
- Trial name
- NCT07235046
- Testing
- DII235, Saline
- Where
- 63 sites in United States, China and 2 more
- Volunteers
- 234 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Therapeutic Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of JP-2266 in Patients with Type 2 Diabetes Mellitus
- Trial name
- NCT06144788
- Testing
- SGLT2 inhibitor
- Where
- South Korea
- Volunteers
- 161 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Type 2 Diabetes, Type 1 Diabetes
European, Open-label, Prospective, Multinational, Multicenter Study in Adult Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home Setting is Considered Routine Practice.
Accu-Chek® Insight Insulin Pump EU Study is a Multicenter Study to evaluate the Accu-Chek® Insight Insulin Pump in routine practice.
- Trial name
- NCT02105103
- Testing
- Accu-Chek® Insight Insulin Pump
- Where
- 8 sites in Austria, United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.